This could include: Heart rate assessment at 4-8 weeks after initiation or dose escalation Periodic electrocardiography if arrhythmias are suspected Patient self-monitoring of pulse if symptomatic palpitations occur Evaluation of heart rate control in patients with atrial fibrillation When evaluating tachycardia in patients on GLP-1 therapy, clinicians should assess for other potential causes, including dehydration (especially from GI side effects), anemia, hyperthyroidism, stimulant use, infection, or other medications
By addressing not only the metabolic challenges but also the cognitive and cardiovascular aspects of bipolar disorder, GLP-1 agonists demonstrate a holistic approach to treatment that may significantly improve patient outcomes
The FDA-approved prescribing information for tirzepatide (Mounjaro and Zepbound) does not list beta blockers as medications that cannot be used concurrently
The t ,semaglutide,SS was comparable between treatment groups, with geometric means of 153, 161 and 158 h in healthy subjects receiving 20 and 40 mg and subjects with T2D receiving 40 mg, respectively, i.e
Your doctor will be able to assess whether semaglutide and Zofran are safe and effective for your specific health condition